Get access

Adoptive immunotherapy for cancer

Authors

  • Marco Ruella,

    1. Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA
    Search for more papers by this author
  • Michael Kalos

    Corresponding author
    1. Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA
    • Correspondence to:

      Michael Kalos

      Lilly Research Laboratories

      Eli Lilly and Company

      450 East, 29th Street

      New York, NY 10016, USA

      Tel.: +1 646-638-5095

      e-mail: kalos_michael_d@lilly.com

    Search for more papers by this author

Summary

Recent clinical success has underscored the potential for immunotherapy based on the adoptive cell transfer (ACT) of engineered T lymphocytes to mediate dramatic, potent, and durable clinical responses. This success has led to the broader evaluation of engineered T-lymphocyte-based adoptive cell therapy to treat a broad range of malignancies. In this review, we summarize concepts, successes, and challenges for the broader development of this promising field, focusing principally on lessons gleaned from immunological principles and clinical thought. We present ACT in the context of integrating T-cell and tumor biology and the broader systemic immune response.

Ancillary